Trial reportScience advances2023
Spleen tyrosine kinase inhibition restores myeloid homeostasis in COVID-19.
Open access · goldAbstract readRandomized Controlled TrialClinical Trial, Phase II
In one paragraph
Trial report in Science advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 26 citations in OpenAlex.
- SARS-CoV-2 Immune Complex-Mediated Neutrophil Activation.Open forum infectious diseases · 2025Trial
- Fostamatinib for Hospitalized Adults With COVID-19 and Hypoxemia: A Randomized Clinical Trial.JAMA network open · 2024Trial
- Low-density neutrophil heterogeneity and spleen tyrosine kinase as therapeutic targets in sepsis.JCI insight · 2026Article
- CD14+CD16- monocytes exhibit NF-κB hyperactivation in biliary atresia: Clinical association and murine therapeutic validation.Hepatology communications · 2026Article
- A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome.British journal of haematology · 2026Article
- Leveraging ADMET Profiling, Network Pharmacology, and Molecular Docking to Evaluate the Repurposing of Product Nkabinde for COVID-19 Treatment.Biomedicines · 2026Article
- Breaking the Stalemate: Advancing Sepsis Therapeutics Beyond Supportive Care.Public health reports (Washington, D.C. : 1974) · 2026Article
- Biological roles and clinical translation of low-density neutrophils in rheumatic, autoimmune and inflammatory diseases: paradigm reconstruction and unresolved questions.Frontiers in immunology · 2026Review
- Association of CD16Journal of inflammation research · 2026Article
- Targeting SYK enhances responses to radiotherapy and PD-1 blockade with myeloid immune remodeling in breast cancer.Frontiers in immunology · 2026Article
- Elevated Spleen Tyrosine Kinase in Low-Density Neutrophils During Bacterial Sepsis in a Nonhuman Primate Model.The Journal of infectious diseases · 2025Article
- Surfactant Protein D and Club Cell Secretory Protein as Biomarkers of Disease Severity and Fostamatinib Efficacy in Severe COVID-19.Critical care explorations · 2025Article
- Prognostic Value of C-Reactive Protein, Procalcitonin, and Interferon-Alpha in COVID-19 and Their Association with PANoptosis: A Cohort Study in Guangxi, China.Journal of inflammation research · 2025Article
- Analysis of phosphomotifs coupled to phosphoproteome and interactome unveils potential human kinase substrate proteins in SARS-CoV-2.Frontiers in cellular and infection microbiology · 2025Article
- Transcriptome analyses reveal common immune system dysregulation in PAH patients andPulmonary circulation · 2024Article
- New insights into SYK targeting in solid tumors.Trends in pharmacological sciences · 2024Review
- HL-60 cells as a valuable model to study LPS-induced neutrophil extracellular traps release.Heliyon · 2024Article
- Innate Immunity in Protection and Pathogenesis During Coronavirus Infections and COVID-19.Annual review of immunology · 2024Review
- Kinome and phosphoproteome reprogramming underlies the aberrant immune responses in critically ill COVID-19 patients.Clinical proteomics · 2024Article
- Maturing neutrophils of lower density associate with thrombocytopenia in Puumala orthohantavirus-caused hemorrhagic fever with renal syndrome.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 9 institutions in 2 countries.
Gustaf WigerbladSystemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Disease, Bethesda, MD, USA.ORCID 0000-0002-1798-4347
Seth A WarnerCritical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD, USA.
Marcos J Ramos-BenitezCritical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD, USA.
Lela KardavaLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, USA.
Xin TianOffice of Biostatistics Research, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA.ORCID 0000-0003-1896-2462
Rui MiaoOffice of Biostatistics Research, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA.ORCID 0000-0001-5046-6341
Robert RegerLaboratory of Transplantation Immunotherapy, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA.
Mala ChakrabortyLaboratory of Transplantation Immunotherapy, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA.
Susan WongLaboratory of Transplantation Immunotherapy, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA.ORCID 0000-0001-7001-5265
Yogendra KanthiLaboratory of Vascular Thrombosis and Inflammation, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA.ORCID 0000-0002-5660-5194
Anthony F SuffrediniCritical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD, USA.ORCID 0000-0003-4179-0902
Stefania Dell'OrsoGenomic Technology Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Stephen BrooksBiodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0001-5592-5332
Christopher KingAdvanced Lung Disease and Lung Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA.
Oksana ShlobinAdvanced Lung Disease and Lung Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA.ORCID 0000-0003-4131-8499
Steven D NathanAdvanced Lung Disease and Lung Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA.
Jonathan CohenAdventist Healthcare Shady Grove Medical Center, Rockville, MD, USA.
Susan MoirLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, USA.ORCID 0000-0002-0163-6911
Richard W ChildsLaboratory of Transplantation Immunotherapy, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA.
Mariana J KaplanSystemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Disease, Bethesda, MD, USA.ORCID 0000-0003-2968-0815
Daniel S ChertowCritical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD, USA.ORCID 0000-0002-1675-1728
Jeffrey R StrichCritical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD, USA.ORCID 0000-0002-5671-1130
National Heart Lung and Blood Institute · USInova Fairfax Hospital · USNational Institute of Allergy and Infectious Diseases · USNational Institute of Arthritis and Musculoskeletal and Skin Diseases · USNational Institutes of Health · USNational Institutes of Health Clinical Center · USUnited States Public Health Service Commissioned Officers Association · USAdventist HealthCare Shady Grove Medical Center · USPonce Health Sciences University · PR
Funding
Systemic AutoimmunityZIAAR041199 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI KAPLAN, MARIANA · 2014 to 2025
$32.5MHigh Throughput Next Generation Sequencing: supports genomics and epigenomics research in muscle, skin, bone and autoimmune diseases.ZICAR041207 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI DELL'ORSO, STEFANIA · 2016 to 2025
$12.3MHuman Translational Studies of Vascular Thrombosis and InflammationZIAHL006262 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI KANTHI, YOGENDRA · 2021 to 2025
$4.7MVascular Immunobiology Mechanistic and Translational StudiesZIAHL006267 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI KANTHI, YOGENDRA · 2021 to 2025
$4.6MUnraveling Cytotoxic and Thrombotic Signals in Host-defense ResponsesZIAHL006263 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI KANTHI, YOGENDRA · 2021 to 2025
$3.5MImmunologic Studies Associated with COVID-19 ZIAAI001325 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MOIR, SUSAN · 2020 to 2025
$1.3MClinical and Molecular Features of Coronavirus Disease 2019ZIACL090070 · CLC · CLINICAL CENTER · PI CHERTOW, DANIEL S · 2020 to 2025
$0kCardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic PersonsZIACL090062 · CLC · CLINICAL CENTER · PI SUFFREDINI, ANTHONY F. · 2020 to 2025
$0kAbstract
Spleen tyrosine kinase (SYK) is a previously unidentified therapeutic target that inhibits neutrophil and macrophage activation in coronavirus disease 2019 (COVID-19). Fostamatinib, a SYK inhibitor, was studied in a phase 2 placebo-controlled randomized clinical trial and was associated with improvements in many secondary end points related to efficacy. Here, we used a multiomic approach to evaluate cellular and soluble immune mediator responses of patients enrolled in this trial. We demonstrated that SYK inhibition was associated with reduced neutrophil activation, increased circulation of mature neutrophils (CD10
Indexed as
COVID-19HLA-DR AntigensHomeostasisHumansOxazinesSyk KinaseHLA-DR AntigensOxazinesSyk Kinase
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.